// App-Quantinova.ai

: A Multicenter Study for the Evaluation of Effectiveness and Safety of Nintendanib in the Treatment of Idiopathic Pulmonary Fibrosis

Researchers

Presenter

  • K. Antoniou

Principal Investigators

  • A. Trachalaki

  • S. Chrysovalantis

  • E. Vasarmidi

  • F. Bardaka

  • E. Bibaki

  • E. Fouka

  • G. Meletis

  • S. Trifon

  • Z. Daniil

  • D. Papakosta

Medical Centers

  • Respiratory Medicine Department, University General Hospital of Herakleion, University of Crete, Herakleion, Greece,

  • Respiratory Medicine Department, Aristotel University, Thessaloniki, Greece,

  • Respiratory Medicine Department, University General Hospital of Thessaly, University of Thessaly, Larissa, Greece,

  • Respiratory Medicine Department, Venizeleion General Hospital, Herakleion, Greece,

  • Respiratory Medicine Department, Papanikolaou General Hospital, Thessaloniki, Greece.

Locations

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

  • Pulmonary arterial hypertension

  • Pulmonary fibrosis

  • Congestive heart failure

  • Hypertension

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved